Effectiveness of hydroxyurea therapy in a cohort of children and adolescents with SCA
| . | Baseline values . | Hydroxyurea MTD . | P . |
|---|---|---|---|
| Age, y | 7.6 ± 4.6 | 10.7 ± 4.3 | — |
| Hemoglobin, g/dL | 8.6 ± 1.3 | 9.7 ± 1.1 | < .001 |
| MCV, fL | 85 ± 6 | 107 ± 13 | < .001 |
| HbF, percentage | 10.6 ± 6.6 | 23.2 ± 7.8 | < .001 |
| ARC, ×109/L | 264 ± 123 | 130 ± 52 | < .001 |
| WBC, ×109/L | 13.6 ± 4.3 | 7.5 ± 3.0 | < .001 |
| ANC, ×109/L | 6.7 ± 2.9 | 3.8 ± 2.2 | < .001 |
| Total bilirubin, mg/dL | 3.0 ± 1.7 | 1.8 ± 1.4 | < .001 |
| LDH, IU/L | 662 ± 326 | 453 ± 220 | < .001 |
| . | Baseline values . | Hydroxyurea MTD . | P . |
|---|---|---|---|
| Age, y | 7.6 ± 4.6 | 10.7 ± 4.3 | — |
| Hemoglobin, g/dL | 8.6 ± 1.3 | 9.7 ± 1.1 | < .001 |
| MCV, fL | 85 ± 6 | 107 ± 13 | < .001 |
| HbF, percentage | 10.6 ± 6.6 | 23.2 ± 7.8 | < .001 |
| ARC, ×109/L | 264 ± 123 | 130 ± 52 | < .001 |
| WBC, ×109/L | 13.6 ± 4.3 | 7.5 ± 3.0 | < .001 |
| ANC, ×109/L | 6.7 ± 2.9 | 3.8 ± 2.2 | < .001 |
| Total bilirubin, mg/dL | 3.0 ± 1.7 | 1.8 ± 1.4 | < .001 |
| LDH, IU/L | 662 ± 326 | 453 ± 220 | < .001 |
Baseline and latest maximum tolerated dose (MTD) laboratory parameters are shown for 111 children receiving long-term (average > 3 years) open-label hydroxyurea therapy at St Jude Children's Research Hospital.
SCA indicates sickle cell anemia; MCV, mean corpuscular volume; HbF, fetal hemoglobin; ARC, absolute reticulocyte count; WBC, white blood cell; ANC, absolute neutrophil count; LDH, lactate dehydrogenase; and —, not applicable.